Evidence map›Paper›PMID 38966016›Full record

ArticleActa clinica Croatica2023

OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.

Antun Gršković, Tanja Ćelić, Josip Španjol, Dean Markić, Bosiljka Devčić, Dragica Bobinac, Sanjin Rački

Abstract read
In one paragraph

Article in Acta clinica Croatica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antun GrškovićDepartment of Urology, Rijeka University Hospital Center, Rijeka, Croatia.
Tanja ĆelićDepartment of Human Anatomy, School of Medicine, University of Rijeka, Rijeka, Croatia.
Josip ŠpanjolDepartment of Urology, Rijeka University Hospital Center, Rijeka, Croatia.
Dean MarkićDepartment of Urology, Rijeka University Hospital Center, Rijeka, Croatia.
Bosiljka DevčićDepartment of Nephrology, Dialysis and Kidney Transplantation, Rijeka University Hospital Center, Rijeka, Croatia.
Dragica BobinacMedical School, Juraj Dobrila University of Pula, Pula, Croatia.
Sanjin RačkiDepartment of Nephrology, Dialysis and Kidney Transplantation, Rijeka University Hospital Center, Rijeka, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is among the most significant health problems, with the associated cardiovascular disease and bone metabolism disorders being the leading cause of morbidity and mortality in these patients. The aim of the study was to determine markers of bone turnover in patient sera (phosphates, calcium, alkaline phosphatase, parathyroid hormone and osteoprotegerin (OPG)) in all stages of kidney failure including kidney transplant recipients. We also wanted to determine whether dialysis vintage affects recovery of bone markers one year after transplantation. There were 164 study patients, whereas 30 healthy individuals served as a control group. Serum OPG progressively increased with decline of the glomerular filtration rate. The highest OPG concentration was recorded in dialysis group. We observed a statistically significant OPG increase in stage 2 CKD. In kidney transplant group, there was positive correlation between OPG and dialysis vintage. We also found that serum OPG was lower in patients treated with dialysis for less than 4 years prior to transplantation. We confirmed that CKD-mineral and bone disorder began in stage 3 CKD with parathyroid hormone and OPG elevation, and a statistically significant OPG increase in stage 2 CKD might be an early sign of CKD-mineral and bone disorder. Dialysis vintage longer than 4 years is associated with more significant disturbances in mineral and bone metabolism.

Indexed as

BiomarkersOsteoprotegerinRenal DialysisAdultAgedChronic Kidney Disease-Mineral and Bone DisorderFemaleGlomerular Filtration RateHumansKidney TransplantationMaleMiddle AgedParathyroid HormoneRenal Insufficiency, ChronicBiomarkersOsteoprotegerinParathyroid HormoneChronic kidney disease–Mineral and bone disorderKidney transplantationOsteoprotegerinRenal dialysisRenal insufficiency, chronic

Identifiers

PMID38966016
PMCPMC11221231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.